Skip to main content
Lipocine Inc. logo

Lipocine Inc. — Investor Relations & Filings

Ticker · LPCN ISIN · US53630X1046 LEI · 549300RXPEQXOJXVBI10 US Manufacturing
Open in API
Filings indexed 788 across all filing types
Latest filing 2013-07-31 Capital/Financing Update
Country US United States of America
Listing US LPCN

About Lipocine Inc.

https://www.lipocine.com/

Lipocine Inc. is a clinical-stage biopharmaceutical company that develops treatments for metabolic, endocrine, and central nervous system disorders. The company leverages its proprietary Lip'ral drug delivery technology to enhance the oral absorption of water-insoluble drugs, aiming to improve patient compliance and therapeutic outcomes. Its portfolio includes TLANDO®, an FDA-approved oral testosterone replacement therapy. Lipocine's development pipeline features candidates for conditions such as non-alcoholic steatohepatitis (NASH), postpartum depression, obesity, and prevention of preterm birth. The company's strategy often involves using the 505(b)(2) regulatory pathway to develop improved formulations of established drugs.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated July 26, 2013. It reports on multiple events: entry into a material definitive agreement involving a private placement of common stock, unregistered sales of equity securities, and a change in the company's independent registered public accounting firm. The document includes detailed descriptions of the securities purchase agreement, registration rights agreement, and the dismissal and engagement of auditors. It also references exhibits including the agreements and a letter from the former auditor. The content focuses on financing activities (private placement of shares) and changes in auditors, which are typical disclosures in an 8-K. The primary focus is on the private placement financing and related agreements, which aligns with Capital/Financing Update filings. The document is not an annual or quarterly report, audit report, or earnings release. It is not a simple announcement or certification but a detailed current report on material events. Therefore, the best fitting category is Capital/Financing Update (CAP).
2013-07-31 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes detailed information about a merger agreement, completion of acquisition, changes in control, and other corporate events. It is not a full annual or quarterly report, nor is it a transcript, presentation, or earnings release. The document is lengthy (15,000 characters) and contains substantive details about the merger and related corporate actions. Form 8-K filings typically fall under Regulatory Filings (RNS) as they are general regulatory announcements and do not fit into more specific categories like M&A filings (which are usually Form 425, DEFM14A, etc.) or Management Reports. Therefore, the best classification is Regulatory Filings (RNS).
2013-07-25 English
FORM 10-Q
Interim / Quarterly Report H1 2013
2013-07-09 English
FORM 10-Q
Interim / Quarterly Report Q1 2013
2013-04-24 English
FORM 10-K
Annual Report FY 2012
2013-02-26 English
10-Q
Interim / Quarterly Report 9M 2012
2012-10-26 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.